Samra S S, Dongre Neelesh, Ballary Chetna, Desai Anish
Department of Cardiac and Vascular Services, St George's Hospitals, Mumbai.
J Indian Med Assoc. 2003 May;101(5):327-8.
A prospective, randomised, double-blind, parallel group study was carried out to compare the efficacy, safety and tolerability of telmisartan 40 mg once daily with losartan 50 mg once daily in Indian patients with mild to moderate hypertension. It had a placebo run-in period of 2 weeks followed by drug treatment (telmisartan 40 mg, once daily or losartan 50 mg once daily) for 8 weeks. Supine BP was assessed at the end of every 2 weeks. Tolerability and safety was assessed by physical examination, laboratory parameters and evaluation of adverse events. Treatment with telmisartan resulted in a significant reduction of SBP of 10.3% and 13.7% as compared to 6.6% and 10.6% in losartan group at the end of 6th and 8th weeks respectively. At the end of 6th and 8th weeks, the reduction was 14.3% and 18.1% among telmisartan which was significantly more as compared to 8.8% and 14.3% in losartan group respectively. The laboratory values were within normal limits. Both drugs were well tolerated. Telmisartan monotherapy in a dose of 40 mg once daily has a clinically better therapeutic effect as compared to losartan 50 mg and a good tolerability profile in patients with mild to moderate hypertension.
一项前瞻性、随机、双盲、平行组研究开展，以比较在印度轻至中度高血压患者中，每日一次服用40毫克替米沙坦与每日一次服用50毫克氯沙坦的疗效、安全性和耐受性。该研究有2周的安慰剂导入期，随后进行为期8周的药物治疗（每日一次服用40毫克替米沙坦或每日一次服用50毫克氯沙坦）。每2周结束时评估仰卧位血压。通过体格检查、实验室参数和不良事件评估来评估耐受性和安全性。与氯沙坦组在第6周和第8周结束时分别降低6.6%和10.6%相比，替米沙坦治疗导致收缩压分别显著降低10.3%和13.7%。在第6周和第8周结束时，替米沙坦组的降低幅度分别为14.3%和18.1%，与氯沙坦组的8.8%和14.3%相比显著更大。实验室值在正常范围内。两种药物耐受性良好。与50毫克氯沙坦相比，每日一次服用40毫克替米沙坦单药治疗在轻至中度高血压患者中具有临床上更好的治疗效果和良好的耐受性。
